Sunday, January 20, 2013

Lobbying And Health Care Costs: A Case Study

Fiscal Footnote:  Big Senate Gift To Drug Makers by Eric Lipton and Kevin Sack.  The New York Times.  January 19, 2013.

The story of the lobbying effort by Amgen, the world's largest biotechnology firm, to delay price restraints for a class of kidney dialysis drugs for two years resulting in costs to Medicare of up to $500 million.

No comments:

Post a Comment